Last reviewed · How we verify
Chronic Airway Disease, Mucus Rheology and Exacerbations: a Randomized Controlled Trial of COPD Patients (COPD-CARhE)
The main objective of this trial is to compare the exacerbation number over 12 months of follow-up between a group of patients with COPD treated according to standardized management (azithromycin prescribed in the event of severe sputum according to the CASA-Q score , standardized comparator arm) and a similar group in which azithromycin is prescribed based on mucus rheology (experimental arm) or CASA-Q.
Details
| Lead sponsor | University Hospital, Montpellier |
|---|---|
| Phase | Phase 4 |
| Status | RECRUITING |
| Enrolment | 72 |
| Start date | 2023-02-03 |
| Completion | 2026-02 |
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
- Azithropycin according to symptoms
- Azithromycin according to rheology or symptoms
Primary outcomes
- The main outcome measure is the number of exacerbations over the 12 months of follow-up. — 12 months
An exacerbation is defined according to French recommendations as an "acute event characterized by worsening of respiratory symptoms (notably cough, sputum and dyspnea) beyond \[normal\] daily variation and leading to a modification of treatment: either a simple increase in bronchodilators (in this case, a duration greater than 24 hours is required to define an exacerbation) or the addition of another treatment (antibiotic therapy and / or oral corticosteroid therapy)."
Countries
France